BMY vs. JNJ, ABBV, MRK, PFE, ZTS, RPRX, JAZZ, CORT, PRGO, and SUPN
Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.
Bristol-Myers Squibb vs.
Bristol-Myers Squibb (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings.
Johnson & Johnson received 34 more outperform votes than Bristol-Myers Squibb when rated by MarketBeat users. However, 66.10% of users gave Bristol-Myers Squibb an outperform vote while only 65.01% of users gave Johnson & Johnson an outperform vote.
Johnson & Johnson has a net margin of 18.20% compared to Bristol-Myers Squibb's net margin of -18.53%. Johnson & Johnson's return on equity of 34.24% beat Bristol-Myers Squibb's return on equity.
76.4% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Bristol-Myers Squibb presently has a consensus target price of $57.86, indicating a potential upside of 3.51%. Johnson & Johnson has a consensus target price of $170.67, indicating a potential upside of 5.04%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts clearly believe Johnson & Johnson is more favorable than Bristol-Myers Squibb.
In the previous week, Johnson & Johnson had 78 more articles in the media than Bristol-Myers Squibb. MarketBeat recorded 141 mentions for Johnson & Johnson and 63 mentions for Bristol-Myers Squibb. Bristol-Myers Squibb's average media sentiment score of 1.48 beat Johnson & Johnson's score of 1.36 indicating that Bristol-Myers Squibb is being referred to more favorably in the media.
Johnson & Johnson has higher revenue and earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.
Bristol-Myers Squibb pays an annual dividend of $2.48 per share and has a dividend yield of 4.4%. Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.1%. Bristol-Myers Squibb pays out -56.1% of its earnings in the form of a dividend. Johnson & Johnson pays out 74.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has raised its dividend for 16 consecutive years and Johnson & Johnson has raised its dividend for 63 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.
Bristol-Myers Squibb has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.
Summary
Johnson & Johnson beats Bristol-Myers Squibb on 16 of the 22 factors compared between the two stocks.
Get Bristol-Myers Squibb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bristol-Myers Squibb Competitors List
Related Companies and Tools
This page (NYSE:BMY) was last updated on 2/22/2025 by MarketBeat.com Staff
Free BMY Stock Alerts